2005
DOI: 10.1007/s00280-005-0159-4 View full text |Buy / Rent full text
|
|

Abstract: Literature on fluoropyrimidine-related neurotoxicity will also be reviewed and possible mechanisms of the drug or its metabolites crossing the blood-brain barrier will be discussed.

Help me understand this report

Search citation statements

Order By: Relevance
Select...
5
0
41
0

Year Published

2008
2008
2011
2011

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

0
41
0
Order By: Relevance
“…Similarly, small amounts of 5FU cross the BBB (Bourke et al 1973;Soni et al 2008). While rare, central neurotoxicity associated with 5FU treatment is well defined and presents most commonly as cerebellar dysfunction with ataxia (Formica et al 2006). This toxicity is usually acute and tends to resolve completely within days, though it can also have delayed onset (Formica et al 2006) and appears to be related to the schedule of administration (Verstappen et al 2003).…”
Section: Discussionmentioning
See 1 more Smart Citation
Create an account to read the remaining citation statements from this report. You will also get access to:
  • Search over 1.2b+ citation statments to see what is being said about any topic in the research literature
  • Advanced Search to find publications that support or contrast your research
  • Citation reports and visualizations to easily see what publications are saying about each other
  • Browser extension to see Smart Citations wherever you read research
  • Dashboards to evaluate and keep track of groups of publications
  • Alerts to stay on top of citations as they happen
  • Automated reference checks to make sure you are citing reliable research in your manuscripts
  • 7 day free preview of our premium features.

Trusted by researchers and organizations around the world

Over 130,000 students researchers, and industry experts at use scite

See what students are saying

rupbmjkragerfmgwileyiopcupepmcmbcthiemesagefrontiersapsiucrarxivemeralduhksmucshluniversity-of-gavle
“…Similarly, small amounts of 5FU cross the BBB (Bourke et al 1973;Soni et al 2008). While rare, central neurotoxicity associated with 5FU treatment is well defined and presents most commonly as cerebellar dysfunction with ataxia (Formica et al 2006). This toxicity is usually acute and tends to resolve completely within days, though it can also have delayed onset (Formica et al 2006) and appears to be related to the schedule of administration (Verstappen et al 2003).…”
Section: Discussionmentioning
“…While rare, central neurotoxicity associated with 5FU treatment is well defined and presents most commonly as cerebellar dysfunction with ataxia (Formica et al 2006). This toxicity is usually acute and tends to resolve completely within days, though it can also have delayed onset (Formica et al 2006) and appears to be related to the schedule of administration (Verstappen et al 2003). In addition, patients with a deficiency in dehydropyrimidine dehydrogenase, which is responsible for the breakdown and clearance of 5FU, are at increased risk for developing neurotoxicity (Verstappen et al 2003).…”
Section: Discussionmentioning
“…18 Five case reports and one case series of capecitabineassociated cerebellar toxicity were identified from a MEDLINE literature search using the keywords capecitabine, cerebellar toxicity, and neurotoxicity. 15,17,[19][20][21][22] Cerebellar ataxia was the sole CNS symptom in two of these cases. 19,22 The other four cases were associated with either toxic encephalopathy or multifocal leukoencephalopathy.…”
Section: Discussionmentioning
“…every three weeks. 15 One case of reversible posterior leukoencephalopathy syndrome associated with bevacizumab has also been reported. 16 The onset of drug-induced cerebellar toxicity may be acute, delayed, or insidious.…”
Section: Discussionmentioning
“…Therefore, it could be speculated that TYMS suppressors are prone to cellular injury. When given intrathecally, 5-FU produces neurological disturbances and neuropathological lesions [18] , and it can cross the brain-blood barrier and cause encephalopathy [22] . The patients in this study revealed to be TYMS suppressors showing TSER 3RC/3RC genotype and homogenous deletion of 6 bp, respectively, suggesting that suppressed TYMS expression would contribute to the 5-FU-related encephalopathy.…”
Section: Discussionmentioning